Metabolomics analysis reveals perturbations of cerebrocortical metabolic pathways in the Pahenu2 mouse model of phenylketonuria

Li-Hua Lu1 | Zheng-Xiang Xia2 | Jia-Lin Guo1 | Ling-Ling Xiao3 | Yong-Jun Zhang4

Abstract

Aims: Phenylketonuria (PKU), which is caused by mutations in the phenylalanine hydroxylase (PAH) gene, is one of the most common inherited diseases of amino acid metabolism. Phenylketonuria is characterized by an abnormal accumulation of phenylalanine and its metabolites in body fluids and brain tissues, subsequently leading to severe brain dysfunction. Various pathophysiological and molecular mechanisms underlying brain dysfunction in PKU have been described. However, the metabolic changes and their impacts on the function of cerebral cortices of patients with PKU remain largely unknown.

Methods: We measured the levels of small molecule metabolites in the cerebrocortical tissues of PKU mice and wild-type control mice using liquid chromatography-mass spectrometry (LC-MS)-based metabolome analysis. Differential metabolites were further subjected to metabolic pathway and enrichment analysis.

Results: Metabolome analysis revealed 35 compounds among 143 detected metabolites were significantly changed in PKU mice as compared to those in their wild-type littersmates. Metabolic pathway and enrichment analysis of these differential metabolites showed that multiple metabolic pathways, including phenylalanine, tyrosine, and tryptophan biosynthesis; valine, leucine, and isoleucine biosynthesis; alanine, aspartate, and glutamate metabolism; purine metabolism; arginine and proline metabolism and methionine metabolism, were impacted in the cerebral cortices of PKU mice.

Conclusions: The data revealed that multiple metabolic pathways in cerebral cortices of PKU mice were disturbed, suggesting that the disturbances of the metabolic pathways might contribute to neurological or neurodevelopmental dysfunction in PKU, which could thus provide new insights into brain pathogenic mechanisms in PKU as well as mechanistic insights for better understanding the complexity of the metabolic mechanisms of the brain dysfunction in PKU.

KEYWORDS

cerebral cortex, metabolic pathway, metabolomics, phenylketonuria

Lu and Xia equally contributed to this work.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.
1 | INTRODUCTION

Phenylketonuria (PKU) is one of the most prevalent autosomal recessive disorders of amino acid metabolism, resulting from a severe deficiency in the activity of the catalytic enzyme phenylalanine hydroxylase (PAH). Phenylalanine hydroxylase dysfunction results in abnormal accumulation of phenylalanine and its metabolites in the plasma, cerebrospinal fluid, and brain tissues, such as the cerebral cortices, subsequently causing neurological and neuropsychiatric disturbances in untreated patients with PKU and even in early treated phenylketonuric patients.2,3 These abnormal disturbances mainly include intellectual disability, impaired emotional regulation, and neurocognitive dysfunction.2,3 Clinical and experimental investigations have highlighted the neurotoxic role of phenylalanine at pathological concentrations in phenylketonuric patients and experimental models of PKU. Adler-Abramovich et al6 observed that phenylalanine self-assembles into amyloid-like deposits and shows cytotoxicity in the hippocampus of PKU model mice and in parietal cortex brain tissue from patients with PKU. Li and colleagues5 discovered that phenylalanine suppresses neurite outgrowth and induces rat cortical neuronal death in vitro by decreasing the expression of the brain-derived neurotrophic factor at both mRNA and protein levels. Moreover, Zhang and Schlegel6,7 demonstrated decreased dendritic arborization of cortical neurons in cultures, reduced dendritic length, and loss of synapses in hippocampal slice cultures after phenylalanine treatment. Despite long-term numerous clinical and experimental studies, the exact pathogenetic mechanisms underlying phenylalanine-evoked impairment of brain function in this neurometabolic disorder remain elusive; in particular, few studies have focused on its metabolic mechanisms.

Metabolomics is a new platform of systems biology, enabling the simultaneous quantitative measurement in complex biological samples of numerous metabolites. As a powerful analytical approach, recently, metabolomics has been increasingly applied in the fields of novel disease biomarker discovery, disease action mechanisms, and evaluation of drug efficacy and toxicity.8 In addition, brain metabolomics has been used for understanding the pathology and identifying potential biomarkers of neurodegenerative diseases in both animal models and human postmortem tissues due to the fact that metabolic changes in the brain are more likely to reflect disease etiology than metabolic changes in peripheral biofluids.9 Thus, a better understanding of the metabolic pathways in brain tissues in PKU may be beneficial for understanding the pathogenesis of PKU and for revealing the potential mechanisms underlying neurological dysfunction or damage in PKU. Therefore, the aim of our study was to characterize the metabolic disturbances in the cerebrocortical tissues in a mouse model of PKU using a metabolomics approach and to elucidate their potential association with brain dysfunction or damage.

2 | MATERIALS AND METHODS

2.1 | Reagents and chemicals

Distilled water was prepared by the Milli-Q purification system. Liquid chromatography-mass spectrometry grade methanol (MeOH) and acetonitrile (ACN) were purchased from Honeywell.
3 | RESULTS

3.1 | Intergroup differences in metabolite profiles in mice revealed by principal component analysis

Principal component analysis (PCA) models are depicted as score plots and consist of two synthetic variables, PC1 and PC2, which account for the greatest proportion of the total variance and the second greatest proportion of the total variance orthogonal to PC1, respectively. The PCA score plots in Figure 1 showed that the scores belonging to the PKU mice grouped distinctly separately from the scores of the wild-type controls in the tested cortical tissue samples. This clearly indicates that significant differences in the metabolome content exist between the wild-type and PKU mice.

3.2 | Identification of differential metabolites in cerebral cortices of PKU mice

Metabolic profiles of cortical samples from the wild-type control and PKU mice were acquired by using LC-MS. Additionally, to explore the differential changes of the 143 identified metabolites between groups, we compared the concentration of each identified metabolite. Finally, a total of 35 metabolic compounds that were significantly altered in the cortical tissues of PKU mice grouped distinctly separately from the scores of the wild-type controls in the tested cortical tissue samples. This clearly indicates that significant differences in the metabolome content exist between the wild-type and PKU mice.

3.3 | Metabolic pathway analysis of differential metabolites

Further pathway and enrichment analyses were carried out in MetaboAnalystR by placing the altered metabolites into their biochemical context. Pathway analysis referencing the KEGG pathway database revealed that a number of metabolic pathways were significantly altered in the cortical tissues of the PKU mice, mainly including phenylalanine, tyrosine, and tryptophan biosynthesis (l-phenylalanine, N-acetyl-l-phenylalanine, phenylactic acid, 5-methoxydimethyltryptamine, hordeine); valine, leucine, and isoleucine biosynthesis (l-valine, l-leucine); alanine, aspartate, and glutamate metabolism (gamma-aminobutyric acid, l-aspartic acid); histidine metabolism (urocanic acid, l-aspartic acid); and arginine and proline metabolism (4-guanidinobutyric acid, gamma-aminobutyric acid) (Figure 4). Enrichment analysis referencing libraries of metabolite sets based on normal metabolism found an additional significantly altered pathway with other contributing metabolites (purine metabolism: adenine, deoxyinosine, glycine, inosine, adenosine, purine; methionine metabolism: γ-methionine, S'-methylthioadenosine, l-aspartic acid) (fold enrichment ≥ 2.0, P < .05, Figure 3).

4 | DISCUSSION

Phenylketonuria is an autosomal recessive disorder caused by a deficiency in the key enzyme PAH, which is necessary for the conversion of the amino acid phenylalanine to tyrosine. The deficiency results in excessive accumulation of phenylalanine and its derived metabolites and development of metabolic encephalopathy. However, the underlying mechanism of brain malfunction has not been completely elucidated yet.

The metabolomics method has recently emerged as a powerful tool for discovering novel diagnostic and therapeutic biomarkers of diseases, elucidating disease action mechanism and evaluating drug efficacy and toxicity by analyzing global metabolic profile changes in various tissue samples. In addition, brain metabolomics has been widely used to understand the pathology and to identify potential biomarkers for neurological diseases, such as neurodegenerative diseases, in both animal models and human postmortem tissues because metabolic changes in the brain are more likely to reflect disease etiology than metabolic changes in peripheral biofluids.

In the present study, LC-MS-based metabolomics analysis of the cerebral cortical tissues of the PAHenu2−/− mice, an ideal mouse model for studying human PKU, revealed significant differences in many metabolites (Table S1, Table 1). Those altered metabolites are involved in many related metabolic pathways, including amino acid metabolism, purine metabolism, and methionine metabolism (Figures 3 and 4). All of these changes occurred in the developing brains of PKU mice aged 4 weeks, indicating that such metabolic disturbances might be closely related to brain dysfunction during brain development in PKU.
major metabolic patterns and plausible pathways associated with brain dysfunction in PKU mice are discussed below. In the present study, cerebrocortical phenylalanine concentrations in PKU mice were dramatically higher than those in wild-type control mice (Table 1), which was consistent with previous studies showing higher phenylalanine concentrations in different brain areas of PKU mice than those in the corresponding brain structures in wild-type controls. Similar results for N-Acetyl-l-phenylalanine and phenyllactic acid were also obtained in this brain region. The enrichment of these phenylalanine-associated metabolites may

| Metabolite name                          | Database ID   | P-valuea | FCb  | Trendc |
|-----------------------------------------|---------------|----------|------|--------|
| L-Phenylalanine                         | HMDB00159     | .0000    | 15.3439 | ↑      |
| N-Acetyl-l-phenylalanine                | HMDB00512     | .0000    | 47.6065 | ↑      |
| 4-Guanidinobutyric acid                 | HMDB03464     | .0003    | 0.7138 | ↓      |
| 5'-Deoxyadenosine                       | HMDB01983     | .0006    | 2.1202 | ↑      |
| Methylguanidine                         | HMDB01522     | .0020    | 1.8503 | ↑      |
| Phenyllactic acid                       | HMDB00779     | .0021    | 32.9758 | ↑      |
| L-Valine                                | HMDB00883     | .0029    | 0.7060 | ↓      |
| α-2-Amino octanoic acid                | HMDB00991     | .0037    | 0.6484 | ↓      |
| Hordenine                               | HMDB04366     | .0052    | 0.5861 | ↓      |
| gamma-Aminobutyric acid                | HMDB00112     | .0054    | 1.2056 | ↑      |
| Deoxycytidine monophosphate            | HMDB01202     | .0068    | 0.4268 | ↓      |
| L-Citrulline                            | HMDB00904     | .0072    | 1.7418 | ↑      |
| Ethanolamine                            | HMDB00149     | .0103    | 0.7753 | ↓      |
| Nicotinic acid adenine dinucleotide    | HMDB01179     | .0110    | 1.8231 | ↑      |
| Purine                                  | HMDB01366     | .0122    | 2.4007 | ↑      |
| Pyridoxal (Vitamin B6)                 | HMDB01545     | .0125    | 3.6546 | ↑      |
| Thiamine monophosphate                 | HMDB02666     | .0154    | 1.3278 | ↑      |
| Urocanic acid                           | HMDB00301     | .0162    | 0.7678 | ↓      |
| 5'-Methylthioadenosine                 | HMDB01173     | .0165    | 1.5250 | ↑      |
| Adenosine                               | HMDB00050     | .0176    | 1.5429 | ↑      |
| L-Methionine                            | HMDB00696     | .0195    | 1.4764 | ↑      |
| L-Aspartic acid                         | HMDB00191     | .0228    | 1.4243 | ↑      |
| Inosine                                 | HMDB00195     | .0245    | 1.2425 | ↑      |
| Folic acid                              | HMDB00121     | .0275    | 0.7067 | ↓      |
| 2-Thiocytidine                          | .0297         | 3.3411   | ↑      |
| 3-Methyluridine                         | HMDB04813     | .0304    | 1.6563 | ↑      |
| Glycine                                 | HMDB00123     | .0311    | 2.0476 | ↑      |
| Glutathione disulfide                   | HMDB03337     | .0331    | 1.3049 | ↑      |
| L-Leucine                               | HMDB00687     | .0354    | 0.7779 | ↓      |
| Deoxyxinosine                           | HMDB00071     | .0360    | 1.6883 | ↑      |
| 3,7-Dimethyluric acid                   | HMDB01982     | .0365    | 0.7705 | ↓      |
| L-Piperolic acid                        | HMDB00716     | .0367    | 1.6126 | ↑      |
| Adenine                                 | HMDB00034     | .0479    | 1.3524 | ↑      |
| Cytidine                                | HMDB00089     | .0489    | 1.3039 | ↑      |
| 5-Methoxydimethyltryptamine             | HMDB02004     | .0490    | 0.4675 | ↓      |

Abbreviation: PKU, phenylketonuria.

aP-value was calculated using the Student's t-test. The metabolites were given in the order of decreasing statistical significance.

bFC, fold change. Values > 1.0 indicate that levels were higher in the cortical tissues of PKU mice; values < 1.0 indicate that levels were lower in the cortical tissues of PKU mice.

c“↑” indicates that the levels were higher in the cortical tissues of PKU mice; “↓” indicates that the levels were lower in the cortical tissues of PKU mice.

TABLE 1 Significantly altered metabolites in cerebral cortices of PKU mice as compared with the wild-type mice (n = 8 mice/group)
FIGURE 2  The heat map of differential metabolites in cerebral cortices of the wild-type and PKU mice. Left, metabolic profiling of cortical samples. Rows and columns indicate samples and metabolites, respectively. The heat map shows the differential metabolite levels in the cerebral cortex of wild-type and PKU mice (green: lowest; red: highest; black: mean). Right, the correlation matrix of differential metabolites. The color saturation of red or blue represents the negative or positive correlation coefficients between metabolites, respectively. PKU, phenylketonuria; WT, wild-type

FIGURE 3  Enrichment analysis of the key metabolites in the cerebral cortex of wild-type and PKU mice
be secondary to the enrichment of the precursor phenylalanine. Previous studies revealed that phenylalanine and its metabolites, such as phenyllactic acid, provoked oxidative stress in the hippocampus and cerebral cortex of developing rats and inhibited cell proliferation, indicating that phenylalanine and its metabolite phenyllactic acid contribute to neurological dysfunction in PKU and might be one explanation for brain dysfunction in PKU.

Branched-chain amino acids (BCAAs) are amino acids structurally characterized by the presence of aliphatic side chains. Branched-chain amino acids in the central nervous system serve as important metabolic precursors required for the biosynthesis of proteins and neurotransmitters, and also serve as important sources of nitrogen, thereby facilitating the synthesis of such essential brain metabolites as glutamate and glutamine.

The results of the present study demonstrate that the levels of valine and leucine, the two BCAAs, were significantly lower in cortical tissues of PKU mice than in those of the wild-type controls (Table 1), suggesting that BCAA metabolism was affected in PKU. Consequently, disturbing BCAA metabolism may adversely affect brain function in PKU by interfering with the biosynthesis of essential proteins, neurotransmitters, or brain metabolites.

Another altered metabolic pathway in PKU mice was the alanine, aspartate, and glutamate pathway. The present study did not reveal an enrichment of alanine and glutamate in the cerebrocortical tissues of PKU mice (data not shown), but demonstrated that there was a significant perturbation of the metabolism pathways of alanine, aspartate, and glutamate (Figure 4) in this brain tissue. Moreover, the present study also revealed a significant enrichment of aspartate and the inhibitory transmitter GABA in the cortical tissues of PKU mice, which could be secondary to a transient enrichment of glutamate, a precursor to GABA. Additionally, a number of studies demonstrated that some amino acids, such as alanine, aspartate, GABA, and glutamate, function as neurotransmitters and/or neuromodulators. All of these findings indicate that the alanine, aspartate, and glutamate metabolic pathway could be involved in the etiology of brain dysfunction in PKU by interfering with some important neurotransmission functions.

Dysregulated purine metabolism has been repeatedly reported to be involved in the pathogenesis of several neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. A recent study conducted by Alonso-Andrés et al revealed that the alterations of purine metabolism are stage- and region-dependent in Alzheimer’s disease by measuring the levels of purine-related metabolites and the activity of their converting enzymes in the frontal, parietal, and temporal cortices of patients with Alzheimer’s disease at different stages of disease. Bourke reported that adenosine or guanosine loading could potentially evoke the disturbances to the A\textsubscript{2A} adenosine receptors in the nigro-striatum or to the guanosine receptors in the hippocampus, amygdala, and ventral striatum, resulting in Parkinson’s disease with dementia. Theoretically, similar pathogenesis could be expected in PKU, a common inherited disease with metabolic defects and neurodegeneration. Interestingly, perturbations of purine metabolism were observed in our present study (Figure 3). Concentrations of nucleosides (adenosine, deoxyinosine, and inosine) were much higher in the cortical tissues of PKU mice than in the wild-type control mice (Table 1), which may suggest a disturbed neuroprotective function leading to neural damage because purine nucleosides play important neuromodulator roles in the central nervous system. In addition, the abnormal recycling
of brain nucleosides is finally reflected in altered levels of other purine metabolites, such as adenine (Table 1). Therefore, we speculated that, in PKU, abnormal purine metabolism may contribute to neurodevelopmental impairment.

Here, we report for the first time the differential metabolomic analysis of cerebral cortex of PKU mouse model and their wild-type littermate controls. The exact mechanisms associated with these altered metabolic pathway in the cortical tissue of PKU mice remain unknown. Nevertheless, it should be noted that additional metabolic pathways, including arginine and proline metabolism and methionine metabolism, were found to be also dysregulated in the cortical tissues of PKU mice (Figures 3 and 4). Disruptions of these metabolic pathways were previously demonstrated to be linked with impaired neurodevelopment or brain dysfunction in various neurodegenerative or neurological diseases. Thus, our study demonstrated that dysregulation of these metabolic pathways may to some extent contribute to the brain pathology associated with PKU.

However, it should be noted that the specific mechanisms underlying the above-mentioned metabolic perturbations, including the enzymes and genes involved, require further investigation. This study provides a new link between PKU and metabolic pathways, including phenylalanine, tyrosine, and tryptophan biosynthesis; valine, leucine, and isoleucine biosynthesis; alanine, aspartate, and glutamate metabolism; purine metabolism; arginine and proline metabolism; and methionine metabolism. These metabolic disturbances may play essential roles in the pathogenesis of brain dysfunction associated with PKU.

### Table 2: Results from metabolic pathway analysis with MetaboAnalystR

| Pathway name                                      | Total cmpd | Hits | Raw P-value | Impact |
|---------------------------------------------------|------------|------|-------------|--------|
| Aminoacyl-tRNA biosynthesis                       | 69         | 6    | .0030       | 0.0000 |
| Arginine and proline metabolism                   | 44         | 4    | .0138       | 0.0424 |
| Valine, leucine and isoleucine biosynthesis       | 11         | 2    | .0225       | 0.6667 |
| Histidine metabolism                              | 15         | 2    | .0408       | 0.1452 |
| Purine metabolism                                 | 68         | 4    | .0574       | 0.0131 |
| Phenylalanine, tyrosine and tryptophan biosynthesis| 4          | 1    | .0848       | 0.5000 |
| Alanine, aspartate and glutamate metabolism       | 24         | 2    | .0949       | 0.3070 |
| Glutathione metabolism                            | 26         | 2    | .1088       | 0.0429 |
| Cysteine and methionine metabolism                | 27         | 2    | .1160       | 0.1122 |
| Cyanobacterial acid metabolism                    | 6          | 1    | .1245       | 0.0000 |
| Thiamine metabolism                               | 7          | 1    | .1437       | 0.0000 |
| Vitamin B6 metabolism                             | 9          | 1    | .1810       | 0.4902 |
| One carbon pool by folate                         | 9          | 1    | .1810       | 0.0000 |
| Methane metabolism                                | 9          | 1    | .1810       | 0.0000 |
| Nitrogen metabolism                               | 9          | 1    | .1810       | 0.0000 |
| Valine, leucine and isoleucine degradation        | 38         | 2    | .2008       | 0.0000 |
| Phenylalanine metabolism                          | 11         | 1    | .2167       | 0.4074 |
| Pyrimidine metabolism                             | 41         | 2    | .2253       | 0.0270 |
| Nicotinate and nicotinamide metabolism            | 13         | 1    | .2508       | 0.1905 |
| Pantothenate and CoA biosynthesis                 | 15         | 1    | .2836       | 0.0000 |
| Folate biosynthesis                               | 16         | 1    | .2994       | 0.0000 |
| beta-Alanine metabolism                           | 17         | 1    | .3149       | 0.0000 |
| Butanoate metabolism                              | 22         | 1    | .3876       | 0.0290 |
| Lysine degradation                                | 23         | 1    | .4012       | 0.0000 |
| Porphyrin and chlorophyll metabolism              | 27         | 1    | .4528       | 0.0000 |
| Glycerophospholipid metabolism                    | 30         | 1    | .4886       | 0.0000 |
| Glycine, serine and threonine metabolism          | 31         | 1    | .5000       | 0.2688 |
| Tyrosine metabolism                               | 44         | 1    | .6279       | 0.0000 |
| Primary bile acid biosynthesis                    | 46         | 1    | .6445       | 0.0298 |

*Total cmpd, the total number of compounds (cmpd) in the pathway.

*Hits, the number of compounds that match with our experimental data.

*Raw P-value, the original P-value calculated from the enrichment analysis.

*Impact, the pathway impact value calculated from pathway topology analysis.
5 | CONCLUSIONS

In conclusion, we report for the first time that multiple metabolic pathways were perturbed in the cerebrocortical regions of PKU mice. Some of these pathways, including phenylalanine, tyrosine, and tryptophan biosynthesis; valine, leucine, and isoleucine biosynthesis; alanine, aspartate, and glutamate metabolism; purine metabolism; arginine and proline metabolism and methionine metabolism, play essential roles in maintaining normal brain function. Therefore, the data suggest that the disturbances of these metabolic pathways might contribute to neurological or neurodevelopmental dysfunction in PKU, which could thus provide new insights into brain pathogenic mechanisms in PKU. The characterization of metabolic abnormalities in this PKU mouse model might provide novel insights into the pathological mechanisms associated with human PKU and might provide useful information for the development of the novel treatment strategy of PKU.

ACKNOWLEDGMENTS

We thank Dr Zheng-Jiang Zhu and Dr Jun-Hao Hu for providing critical suggestions and assistance in the metabolomics analysis. We are also grateful to Hao He and Jia-Ning Dai for technical assistance. The National Natural Science Foundation of China (No. 81300708) supported this work.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ORCID

Yong-Jun Zhang https://orcid.org/0000-0001-9326-1012

REFERENCES

1. Lu L, Gu X, Li D, Liang L, Zhao Z, Gao J. Mechanisms regulating superoxide generation in experimental models of phenylketonuria: an essential role of NADPH oxidase. Mol Genet Metab. 2011:104:241-248.
2. Janzen D, Nguyen M. Beyond executive function: non-executive cognitive abilities in individuals with PKU. Mol Genet Metab. 2010;99(Suppl 1):S47-S51.
3. Christ SE, Huijbregts SC, de Sonneville LM, White DA. Executive function in early-treated phenylketonuria: profile and underlying mechanisms. Mol Genet Metab. 2010;99(Suppl 1):S22-S32.
4. Adler-Abramovich L, Vaks L, Carny O, et al. Phenylalanine assembly into toxic fibrils suggests amyloid etiology in phenylketonuria. Nat Chem Biol. 2012;8:701-706.
5. Li D, Gu X, Lu L, Liang L. Effects of phenylalanine on the survival and neurite outgrowth of rat cortical neurons in primary cultures: possible involvement of brain-derived neurotrophic factor. Mol Cell Biochem. 2010;339:1-7.
6. Zhang Y, Zhang H, Yuan X, Gu X. Differential effects of phenylalanine on Rac1, Cdc42, and RhoA expression and activity in cultured cortical neurons. Pediatr Res. 2007;62:8-13.
7. Schlegel G, Scholz R, Ullrich K, Santer R, Rune GM. Phenylketonuria: direct and indirect effects of phenylalanine. Exp Neurol. 2016;281:28-36.
8. Zhang H, Zhao Y, Xia Z, et al. Metabolic profiles revealed anti-ischemia-reperfusion injury of Yangxinshi tablet in Rats. J Ethnopharmacol. 2018;214:124-133.
9. He J, Zhu Y, Aa J, et al. Brain metabolic changes in rats following acoustic trauma. Front Neurosci. 2017;11:148.
10. Cai Y, Weng K, Guo Y, Peng J, Zhu Z. An integrated targeted metabolomic platform for high-throughput metabolite profiling and automated data processing. Metabolomics. 2015;11:1575-1586.
11. Xia J, Wishart DS. Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis. Curr Protoc Bioinf. 2016;55:14.10.1-14.10.91.
12. Fernandes CG, Leipnitz G, Seminotti B, et al. Experimental evidence that phenylalanine provokes oxidative stress in hippocampus and cerebral cortex of developing rats. Cell Mol Neurobiol. 2010;30:317-326.
13. Oberdoerster J, Guizzetti M, Costa LG. Effect of phenylalanine and its metabolites on the proliferation and viability of neuronal and astroglial cells: possible relevance in maternal phenylketonuria. J Pharmacol Exp Ther. 2000;295:295-301.
14. Sharma B, Lawrence DW, Hutchison MG. Branched chain amino acids (BCAAs) and traumatic brain injury: a systematic review. J Head Trauma Rehabil. 2018;33:33-45.
15. Engskog MK, Ersson L, Hagløf J, Arvidsson T, Pettersson C, Brittebo E. β-N-Methylamino-γ-alanine (BMAA) perturbs alanine, aspartate and glutamate metabolism pathways in human neuroblastoma cells as determined by metabolic profiling. Amino Acids. 2017;49:905-919.
16. García-Esparcia P, Hernández-Ortega K, Ansoleaga B, Carmona M, Ferrer I. Purine metabolism gene deregulation in Parkinson's disease. Neuropathol Appl Neurobiol. 2015;41:926-940.
17. Bourke CA. Astrocyte dysfunction following molybdenum-associated purine loading could initiate Parkinson's disease with dementia. NPJ Parkinsons Dis. 2018;4:7.
18. Alonso-Andrés P, Albasanz JL, Ferrer I, Martín M. Purine-related metabolites and their converting enzymes are altered in frontal, parietal and temporal cortex at early stages of Alzheimer's disease pathology. Brain Pathol. 2018;28:933-946.
19. Sebastião AM, Ribeiro JA. Neuromodulation and metamodulation by adenosine: impact and subtleties upon synaptic plasticity regulation. Brain Res. 2015;1621:102-113.
20. Zhang M, Liu Y, Liu M, et al. UHPCL-QTOF/MS-based metabolomics investigation for the protective mechanism ofDanshen in Alzheimer's disease cell model induced by Aβ1-42. Metabolomics. 2019;15:13.
21. Singhal NK, Freeman E, Arning E, et al. Dysregulation of methionine metabolism in multiple sclerosis. Neurochem Int. 2018;112:1-4.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Lu L-H, Xia Z-X, Guo J-L, Xiao L-L, Zhang Y-J. Metabolomics analysis reveals perturbations of cerebrocortical metabolic pathways in the Pkal−/− mouse model of phenylketonuria. CNS Neurosci Ther. 2020;26:486-493. https://doi.org/10.1111/cns.13214